{
  "nct_id": "NCT05904886",
  "age": "Adults",
  "cancer_center_accrual_goal_upper": 0,
  "curated_on": "2023-06-15",
  "study_start_date": "2023-09-14",
  "study_completion_date": "",
  "data_table4": "Interventional",
  "drug_list": {
    "drug": [
      {
        "drug_name": "Other: Placebo"
      },
      {
        "drug_name": "Drug: Tiragolumab"
      },
      {
        "drug_name": "Drug: Bevacizumab"
      },
      {
        "drug_name": "Drug: Atezolizumab"
      }
    ]
  },
  "long_title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma",
  "last_updated": "2025-08-26",
  "management_group_list": {
    "management_group": [
      {
        "is_primary": "Y",
        "management_group_name": "Group1"
      }
    ]
  },
  "oncology_group_list": {
    "oncology_group": [
      {
        "group_name": "Group1",
        "is_primary": "N"
      }
    ]
  },
  "phase": "PHASE3",
  "principal_investigator": "NA, Stephen Chan",
  "principal_investigator_institution": "Hoffmann-La Roche, CUHK",
  "program_area_list": {
    "program_area": [
      {
        "is_primary": "Y",
        "program_area_name": "Program1"
      }
    ]
  },
  "protocol_id": 0,
  "protocol_ids": [
    "HCC077"
  ],
  "protocol_no": "",
  "protocol_target_accrual": 650,
  "protocol_type": "INTERVENTIONAL",
  "prior_treatment_requirements": [
    "Inclusion Criteria:",
    "* Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants",
    "* Disease that is not amenable to curative surgical and/or locoregional therapies",
    "* No prior systemic treatment for locally advanced or metastatic and/or unresectable HCC",
    "* Measurable disease according to RECIST v1.1",
    "* ECOG Performance Status of 0 or 1 within 7 days prior to randomization",
    "* Child-Pugh Class A within 7 days prior to randomization",
    "* Adequate hematologic and end-organ function",
    "* Female participants of childbearing potential must be willing to avoid pregnancy within 5 months after the final dose of atezolizumab, within 6 months after the final dose of bevacizumab, and within 90 days after the final dose of tiragolumab/placebo",
    "* Male participants with a female partner of childbearing potential or pregnant female partner must remain abstinent or use a condom during the treatment period and for 6 months after the final dose of bevacizumab and for 90 days after the final dose of tiragolumab/placebo to avoid exposing the embryo.",
    "Exclude - Exclusion Criteria:",
    "Exclude - * Pregnancy or breastfeeding within 5 months after the final dose of atezolizumab, within 6 months after the final dose of bevacizumab, and within 90 days after the final dose of tiragolumab/placebo",
    "Exclude - * Prior treatment with CD137 agonists or immune checkpoint blockade therapies",
    "Exclude - * Treatment with investigational therapy within 28 days prior to initiation of study treatment",
    "Exclude - * Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure",
    "Exclude - * Treatment with systemic immunostimulatory agents",
    "Exclude - * Treatment with systemic immunosuppressive medication",
    "Exclude - * Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding",
    "Exclude - * A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment",
    "Exclude - * Active or history of autoimmune disease or immune deficiency",
    "Exclude - * History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan",
    "Exclude - * History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death",
    "Exclude - * Mixed histology or other subtypes/variants of HCC, including, but not limited to, known liver adenocarcinoma, fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC",
    "Exclude - * Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)",
    "Exclude - * Acute Epstein-Barr virus (EBV) infection or known or suspected chronic active EBV infection",
    "Exclude - * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases."
  ],
  "short_title": "A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)",
  "site_list": {
    "site": []
  },
  "sponsor_list": {
    "sponsor": [
      {
        "is_principal_sponsor": "Y",
        "sponsor_name": "Hoffmann-La Roche",
        "sponsor_protocol_no": "",
        "sponsor_roles": "sponsor"
      }
    ]
  },
  "staff_list": {
    "protocol_staff": []
  },
  "status": "open to accrual",
  "summary": "The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC).",
  "treatment_list": {
    "step": [
      {
        "step_internal_id": 111,
        "step_code": "1",
        "step_type": "Registration",
        "arm": [
          {
            "arm_code": "Atezolizumab + Bevacizumab + Tiragolumab",
            "arm_internal_id": 0,
            "arm_description": "Atezolizumab plus bevacizumab plus tiragolumab will be administered every 3 weeks (Q3W) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.",
            "arm_suspended": "N",
            "dose_level": [
              {
                "level_code": "0",
                "level_description": "Drug: Atezolizumab",
                "level_internal_id": 0,
                "level_suspended": "N"
              },
              {
                "level_code": "1",
                "level_description": "Drug: Bevacizumab",
                "level_internal_id": 1,
                "level_suspended": "N"
              },
              {
                "level_code": "2",
                "level_description": "Drug: Tiragolumab",
                "level_internal_id": 2,
                "level_suspended": "N"
              }
            ]
          },
          {
            "arm_code": "Atezolizumab + Bevacizumab + Placebo",
            "arm_internal_id": 1,
            "arm_description": "Atezolizumab, bevacizumab plus placebo will be administered every 3 weeks (Q3W) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.",
            "arm_suspended": "N",
            "dose_level": [
              {
                "level_code": "0",
                "level_description": "Drug: Atezolizumab",
                "level_internal_id": 0,
                "level_suspended": "N"
              },
              {
                "level_code": "1",
                "level_description": "Drug: Bevacizumab",
                "level_internal_id": 1,
                "level_suspended": "N"
              },
              {
                "level_code": "2",
                "level_description": "Other: Placebo",
                "level_internal_id": 2,
                "level_suspended": "N"
              }
            ]
          }
        ],
        "match": [
          {
            "clinical": {
              "age_numerical": ">=18",
              "disease_status": [
                "Locally Advanced",
                "Metastatic",
                "Unresectable",
                "Untreated"
              ],
              "oncotree_primary_diagnosis": "Hepatocellular Carcinoma"
            }
          }
        ]
      }
    ]
  }
}